Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus Dosing

KA Birdwell; B Decker; JM Barbarino; JF Peterson; CM Stein; W Sadee; D Wang; AA Vinks; Y He; JJ Swen; JS Leeder; Ron van Schaik; KE Thummel; TE Klein; KE Caudle; IAM MacPhee

doi:10.1002/cpt.113

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus Dosing

KA Birdwell
, B Decker
, JM Barbarino
, JF Peterson
, CM Stein
, W Sadee
, D Wang
, AA Vinks
, Y He
, JJ Swen
, JS Leeder
, Ron van Schaik
, KE Thummel
, TE Klein
, KE Caudle
, IAM MacPhee

Clinical Chemistry

Research output: Contribution to journal › Article › Academic › peer-review

650 Citations (Scopus)

Abstract

Tacrolimus is the mainstay immunosuppressant drug used after solid organ and hematopoietic stem cell transplantation. Individuals who express CYP3A5 (extensive and intermediate metabolizers) generally have decreased dose-adjusted trough concentrations of tacrolimus as compared with those who are CYP3A5 nonexpressers (poor metabolizers), possibly delaying achievement of target blood concentrations. We summarize evidence from the published literature supporting this association and provide dosing recommendations for tacrolimus based on CYP3A5 genotype when known (updates at www.pharmgkb.org).

Original language	Undefined/Unknown
Pages (from-to)	19-24
Number of pages	6
Journal	Clinical Pharmacology & Therapeutics
Volume	98
Issue number	1
DOIs	https://doi.org/10.1002/cpt.113
Publication status	Published - 2015

Research programs

EMC MM-01-25-01

Access to Document

10.1002/cpt.113

Cite this

Birdwell, KA., Decker, B., Barbarino, JM., Peterson, JF., Stein, CM., Sadee, W., Wang, D., Vinks, AA., He, Y., Swen, JJ., Leeder, JS., van Schaik, R., Thummel, KE., Klein, TE., Caudle, KE., & MacPhee, IAM. (2015). Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus Dosing. Clinical Pharmacology & Therapeutics, 98(1), 19-24. https://doi.org/10.1002/cpt.113

@article{a833ab9a2a624e48b427121b3f4e6b65,

title = "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus Dosing",

abstract = "Tacrolimus is the mainstay immunosuppressant drug used after solid organ and hematopoietic stem cell transplantation. Individuals who express CYP3A5 (extensive and intermediate metabolizers) generally have decreased dose-adjusted trough concentrations of tacrolimus as compared with those who are CYP3A5 nonexpressers (poor metabolizers), possibly delaying achievement of target blood concentrations. We summarize evidence from the published literature supporting this association and provide dosing recommendations for tacrolimus based on CYP3A5 genotype when known (updates at www.pharmgkb.org).",

author = "KA Birdwell and B Decker and JM Barbarino and JF Peterson and CM Stein and W Sadee and D Wang and AA Vinks and Y He and JJ Swen and JS Leeder and \{van Schaik\}, Ron and KE Thummel and TE Klein and KE Caudle and IAM MacPhee",

year = "2015",

doi = "10.1002/cpt.113",

language = "Undefined/Unknown",

volume = "98",

pages = "19--24",

journal = "Clinical Pharmacology \& Therapeutics",

issn = "0009-9236",

publisher = "Wiley-Blackwell",

number = "1",

}

Birdwell, KA, Decker, B, Barbarino, JM, Peterson, JF, Stein, CM, Sadee, W, Wang, D, Vinks, AA, He, Y, Swen, JJ, Leeder, JS, van Schaik, R, Thummel, KE, Klein, TE, Caudle, KE & MacPhee, IAM 2015, 'Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus Dosing', Clinical Pharmacology & Therapeutics, vol. 98, no. 1, pp. 19-24. https://doi.org/10.1002/cpt.113

TY - JOUR

T1 - Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus Dosing

AU - Birdwell, KA

AU - Decker, B

AU - Barbarino, JM

AU - Peterson, JF

AU - Stein, CM

AU - Sadee, W

AU - Wang, D

AU - Vinks, AA

AU - He, Y

AU - Swen, JJ

AU - Leeder, JS

AU - van Schaik, Ron

AU - Thummel, KE

AU - Klein, TE

AU - Caudle, KE

AU - MacPhee, IAM

PY - 2015

Y1 - 2015

N2 - Tacrolimus is the mainstay immunosuppressant drug used after solid organ and hematopoietic stem cell transplantation. Individuals who express CYP3A5 (extensive and intermediate metabolizers) generally have decreased dose-adjusted trough concentrations of tacrolimus as compared with those who are CYP3A5 nonexpressers (poor metabolizers), possibly delaying achievement of target blood concentrations. We summarize evidence from the published literature supporting this association and provide dosing recommendations for tacrolimus based on CYP3A5 genotype when known (updates at www.pharmgkb.org).

AB - Tacrolimus is the mainstay immunosuppressant drug used after solid organ and hematopoietic stem cell transplantation. Individuals who express CYP3A5 (extensive and intermediate metabolizers) generally have decreased dose-adjusted trough concentrations of tacrolimus as compared with those who are CYP3A5 nonexpressers (poor metabolizers), possibly delaying achievement of target blood concentrations. We summarize evidence from the published literature supporting this association and provide dosing recommendations for tacrolimus based on CYP3A5 genotype when known (updates at www.pharmgkb.org).

U2 - 10.1002/cpt.113

DO - 10.1002/cpt.113

M3 - Article

C2 - 25801146

SN - 0009-9236

VL - 98

SP - 19

EP - 24

JO - Clinical Pharmacology & Therapeutics

JF - Clinical Pharmacology & Therapeutics

IS - 1

ER -